Purilogics, a company recognized for its best-in-class membrane chromatography technology, development, and commercialization, is excited to announce that it has been awarded a significant grant from the National Institutes of Health (NIH) to support the research and development of first-in-market high-capacity, -selectivity, and -throughput affinity membranes for the purification of mRNA. With a grant amount of $1.7M from the Small Business Innovation Research (SBIR) program, Purilogics aims to develop mRNA affinity membranes with enabling accelerated purifications for both small and large mRNAs, as well as create and conduct field research on prototypes through industry collaboration.

We are excited to attend Bioprocessing Summit from August 13 to August 16, 2019 in Boston, MA. Drs. Graham Temples and Jinxiang Zhou will present latest data for our PurexaTM-MQ and PurexaTM-A chromatographic membrane technologies.